← Issue №17/
week of Oct 25, 2026/
the whole section, in full
Hepatology, in full.
All 12 Hepatology papers in this issue,
as full cards, ranked by clinical utility. The issue page carries the strongest few;
this is the section, whole.
Actionability = is there something to do. Prevalence = how much of a general GI practice it touches. Stakes = how consequential the decision is. Evidence strength = how far the study design and the result support the action. Novelty = how likely you are not already doing it.
Hepatologyprospective cohort · n=3,600,000 · Oct 20, 2026 · Ann Intern Med · IF 19.6
New evidenceviral hepatitispediatricepidemiologyhealth services
Clinical takeawayAdvocate for universal birth-dose HBV vaccination in infants to prevent chronic HBV infections and reduce susceptibility.
What it foundShared decision-making vaccination strategy increases childhood chronic HBV infections by 83% (467 vs 255) compared to universal birth-dose vaccination.
ContextChallenges the proposed shared decision-making strategy, confirming the superiority of universal birth-dose vaccination in preventing chronic HBV infections.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Mohareb AM … Hyle EP · Annals of Internal Medicine · IF 19.6 · PubMed ↗Permalink
Hepatologyguideline · Oct 22, 2026 · Hepatology · IF 18.0
Clinical takeawayUse UDCA first line, PPAR agonists for inadequate response or intolerance, liver stiffness measurement for prognostication, linerixibat for moderate to severe pruritus, and UDCA after transplant to reduce recurrence; certainty across the 6 recommendations ranged from moderate to very low.
What it foundThe guideline provides 6 recommendations, including UDCA as first-line therapy, liver stiffness measurement for prognostication, and linerixibat for moderate to severe pruritus.
ContextThis guideline refines current practice by providing evidence-based recommendations for diagnosis, treatment escalation, symptom management, and post-transplant care in adults with PBC.
Measured against the standard of care· AGA/AASLD 2026 Clinical Practice Guideline (Gastroenterology 2026;171(5):817-839; Hepatology 2026), complementing AASLD 2018/2021 Practice GuidanceShowHide
Decision at stakethe use of UDCA as first-line therapy for PBC
Adults with PBC: ursodeoxycholic acid (UDCA) is first-line for every patient, started at diagnosis (a strong recommendation); the 13-15 mg/kg/d dose comes from the 2018/2021 AASLD guidance, which the 2026 guideline adds to rather than replaces.…If the response to UDCA is inadequate, consider adding a PPAR agonist; if UDCA is not tolerated, consider a PPAR agonist instead.…After liver transplant for PBC, give UDCA prophylaxis to reduce recurrence and graft failure.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Adults with PBC: ursodeoxycholic acid (UDCA) is first-line for every patient, started at diagnosis (a strong recommendation); the 13-15 mg/kg/d dose comes from the 2018/2021 AASLD guidance, which the 2026 guideline adds to rather than replaces. If antimitochondrial antibodies (AMA) are negative and PBC is suspected, test for the PBC-specific antinuclear antibodies SP100 and GP210, which may avoid a liver biopsy. Measure liver stiffness (elastography) to estimate the risk of progression; the guideline says the best interval for repeat elastography is unknown. If the response to UDCA is inadequate, consider adding a PPAR agonist; if UDCA is not tolerated, consider a PPAR agonist instead. The patient summary names seladelpar and elafibranor, which have FDA accelerated approval as second-line drugs and are not recommended in decompensated cirrhosis. Off-label fibrates (bezafibrate, fenofibrate) are discouraged in decompensated cirrhosis. Obeticholic acid is no longer a US option: it was withdrawn from the market in late 2025, and the 2026 guideline makes no recommendation on it. For moderate-to-severe cholestatic pruritus, consider the IBAT inhibitor linerixibat through shared decision-making that weighs its GI side effects (diarrhea, abdominal pain), cost and patient preference; the older bile-acid sequestrant, rifampin, naltrexone and sertraline ladder from the 2021 guidance still applies. After liver transplant for PBC, give UDCA prophylaxis to reduce recurrence and graft failure. Certainty of evidence ranges from moderate to very low. The guideline found too little evidence to recommend anything for patients who do not respond to second-line therapy, and the long-term effect of PPAR agonists on mortality, transplant-free survival and decompensation is not established.
New evidencecirrhosisportal hypertensionhepatocellular carcinomavariceal bleeding
Clinical takeawayConsider using SAPHE-R to rule out varices in patients with HCC and compensated advanced chronic liver disease, avoiding unnecessary endoscopy in those meeting SAPHE-R criteria.
What it foundSAPHE-R (LSM≤16 kPa, platelet count ≥160×10⁹/L, ALBI grade 1) missed 4.0% of varices and 3.0% of high-risk varices, sparing 17.6% of UGE, compared to Baveno VI criteria which missed 8.5% of varices and 6.0% of HRV.
ContextChallenges Baveno VI criteria in HCC patients with compensated advanced chronic liver disease, offering a more reliable non-invasive alternative for variceal risk assessment in this population.
Refinessuggested applicable standard· American Association for the Study of Liver Diseases (AASLD), Kaplan DE, Ripoll C, Thiele M, et al. "AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis." Hepatology. 2024;79(5):1180-1211.ShowHide
Decision at stakenon-invasive rule-out of varices in patients with HCC and cACLD
…Risk-stratify compensated advanced chronic liver disease (cACLD) with non-invasive tests before defaulting to endoscopy. By vibration-controlled transient elastography, liver stiffness (LSM) under 10 kPa excludes cACLD, 10 to 14.9 kPa is suggestive and warrants further testing, and 15 kPa or above rules cACLD in.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Scope: this primary document covers portal hypertension and varices in cirrhosis ONLY. Everything else in the current entry (HCC surveillance, transplant referral, nutrition, vaccination, ascites/SBP/HE/HRS/ACLF management) belongs to the separate documents listed as supporting sources and must not be attributed to this guidance. Risk-stratify compensated advanced chronic liver disease (cACLD) with non-invasive tests before defaulting to endoscopy. By vibration-controlled transient elastography, liver stiffness (LSM) under 10 kPa excludes cACLD, 10 to 14.9 kPa is suggestive and warrants further testing, and 15 kPa or above rules cACLD in. Clinically significant portal hypertension (CSPH, i.e. HVPG above 10 mm Hg) is ruled in non-invasively by LSM at or above 25 kPa alone, or LSM 20 to 24.9 kPa with platelets below 150 x 10^9/L, or LSM 15 to 19.9 kPa with platelets below 110 x 10^9/L. Where spleen stiffness measurement is available, values below 21 kPa argue against CSPH and above 50 kPa argue for it. These non-invasive cutoffs are conditional probability thresholds, not universal diagnostic rules, and hold only when their derivation conditions are met. They were established in compensated advanced chronic liver disease of viral (treated or untreated HBV/HCV), alcohol-related, or non-obese (BMI under 30) MASLD etiology, and are not validated for and should not be applied to cholestatic (e.g. PBC, PSC), vascular, or other etiologies, in which different cutoffs apply. They also require a technically reliable liver stiffness measurement by vibration-controlled transient elastography, fasting, at least 10 valid acquisitions, and an IQR/median ratio below 30 percent, and are confounded by factors that raise liver stiffness independently of fibrosis, including ALT flares or acute hepatitis, extrahepatic cholestasis, hepatic congestion (right heart failure), and recent food intake; Baveno VII recommends confirming an LSM-based rule-in on a repeat measurement obtained on a separate day. The spleen stiffness cutoffs apply only to a dedicated 100 Hz spleen module, carry a higher technical failure rate, are machine-dependent, and are not interchangeable with values obtained using the standard 50 Hz liver probe. Where these population or acquisition conditions are not met, the numeric thresholds do not reliably classify CSPH, and HVPG measurement or endoscopy is required rather than a non-invasive determination. Preserve the gray zone: LSM 15 to 25 kPa without a qualifying platelet count is explicitly indeterminate (roughly 40 to 60 percent of cACLD patients) and calls for HVPG and/or endoscopy rather than assumption in either direction. Once CSPH is established, offer a non-selective beta-blocker, carvedilol preferred at 12.5 mg/day, to lower portal pressure and prevent FIRST decompensation, on the strength of PREDESCI. This is a treat-the-pressure strategy rather than a treat-the-varices one: because a patient already on NSBB for CSPH would not have management changed by the finding, screening endoscopy becomes unnecessary for most such patients. Screening EGD is still indicated where elastography is unavailable, technically difficult, or gives discordant results, and for patients who do not meet non-invasive criteria. Standard beta-blocker contraindications (severe asthma, advanced heart block, bradyarrhythmias) continue to apply. For varices needing treatment managed endoscopically, band ligation is repeated every 2 to 4 weeks until obliteration, with surveillance endoscopy at 6 months and annually thereafter. Gastric/cardiofundal varices are treated with cyanoacrylate injection or EUS-guided coil embolization rather than banding, with hepatology involvement. In acute variceal hemorrhage, consider preemptive (early) TIPS within 24 to 72 hours in high-risk patients: Child-Turcotte-Pugh class B with score above 7 and active bleeding at endoscopy despite vasoactive therapy, or CTP class C with score 10 to 13. Keep the document's own qualifier: there is no established universal MELD or CTP cutoff at which TIPS is mandatory, and the decision is case-by-case with hepatology consultation. Statin use in compensated cirrhosis is NOT a recommendation traceable to this document; the current entry's statin sentence needs its own source or removal. Verification note: the Hepatology full text is paywalled (402/403 on direct fetch). Document identity, title, year, volume, pages and authorship were confirmed via Crossref and PubMed metadata; the numeric thresholds above were corroborated from two independent peer-reviewed commentaries on this specific guidance and match the Baveno VII rule-of-five, but were not read verbatim from the primary PDF. A human should confirm the exact guidance-statement wording against the full text before this entry is treated as quotation-grade.
Clinical takeawayAn LFI change of 0.4 is a candidate minimal clinically important difference for frailty programmes; this cohort cannot show that prehabilitation itself lowers mortality, and 6MWT gains did not track survival.
What it foundLiver frailty index (LFI) improvement by at least 0.4 was associated with a ∼50% reduction in mortality (HR=0.56, p=0.037).
ContextThis study provides evidence supporting the use of prehabilitation to improve frailty metrics and survival in liver transplant candidates, refining prior evidence on frailty interventions. The findings apply specifically to LT candidates with a median age of 57 and MELD score of 14.
Emergingsuggested applicable standard· AASLD/AST, 'AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation' (Dove L et al., Hepatology 2026;83(6):1609-1645). DOI 10.1097/HEP.0000000000001644, PMID 41405234.ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Refer patients with decompensated cirrhosis (including those with MELD-Na <15 or MELD 3.0 <15 if they have clinically significant portal hypertension, recurrent ascites, hepatic encephalopathy, or variceal bleeding), acute liver failure meeting King's College Criteria/UNOS Status 1A, or HCC within Milan/UCSF criteria for comprehensive multidisciplinary liver transplant evaluation, with MELD 3.0 driving UNOS waitlist allocation and MELD exception scoring for HCC/HPS/FAP. Optimize modifiable risk factors before listing (alcohol abstinence, HCV DAA treatment, vaccinations, DM/obesity/OSA and dental clearance) and use bridging/downstaging locoregional therapy for HCC while awaiting transplant. After transplant, maintain lifelong immunosuppression with tacrolimus plus mycophenolate ± tapered steroids alongside infection prophylaxis and recurrent-disease surveillance.
Lin FP … Duarte-Rojo A · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Hepatologyprospective cohort · n=8,034 · Oct 22, 2026 · J Clin Gastro · IF 2.9
Clinical takeawayAsking MASLD patients about fatigue, itch and sleep is reasonable; the registry documents the burden, not that screening or any treatment improves it.
What it found25% of MASLD patients reported significant pruritus, 35% significant fatigue, and 34% sleep disorders, with fatigue independently predicting impaired HRQL and work productivity loss.
ContextConfirms and quantifies the high burden of fatigue, pruritus, and sleep disorders in MASLD, previously suspected but not systematically documented in a large global cohort. Multivariate analyses showed pruritus and sleep disorders independently predict fatigue.
Measured against the standard of care· EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798)ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range. The AGA 2026 MetALD update sets MetALD at about 140-350 g/week of alcohol in women and 210-420 g/week in men, averaged over at least 3 months. MASLD therefore means under about 140 g/week (women) or 210 g/week (men), and drinking above the MetALD range is ALD. Assess alcohol use in every patient with steatotic liver disease at diagnosis and at least once a year, by interview, a validated questionnaire (e.g., AUDIT-C) and/or biomarkers such as phosphatidylethanol (PEth). Advise every patient with steatotic liver disease to stop drinking. Screen people with type 2 diabetes, people with overweight or obesity plus at least one more metabolic risk factor, and anyone with incidental steatosis or raised aminotransferases. Use FIB-4 first. A score below 1.3 (below 2.0 at age 65 or older) is low risk: the patient stays in primary care and repeats FIB-4 every 1-2 years. A score at or above the cutoff goes to a second-line test: VCTE, or ELF if elastography is not available. VCTE below 8 kPa is low risk. VCTE of 8 kPa or more, or ELF of 9.2 or more, means clinically significant fibrosis is likely and the patient should be referred to hepatology. Read liver stiffness with caution if the patient is actively drinking. Reserve biopsy for discordant or unclear results. Lifestyle change is the base of treatment for everyone: at least 5% weight loss improves steatosis, and 10% or more is usually needed for fibrosis to improve. Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. The NIT ranges that stand in for F2-F3 differ by society. AASLD uses VCTE 8-15 kPa, MRE 3.1-4.4 kPa or ELF 9.2-10.5. EASL-EASD-EASO 2026 frames the treatable high-risk group as, for example, VCTE 10-20 kPa, MRE 3.1-5.0 kPa or ELF 9.8-11.3. Two drugs are approved: resmetirom (80 mg oral daily, or 100 mg at body weight of 100 kg or more; AASLD Oct 2024 guidance) and semaglutide 2.4 mg subcutaneously once weekly (FDA accelerated approval Aug 2025, AASLD Nov 2025 guidance; in ESSENCE, MASH resolved without fibrosis worsening in 62.9% vs 34.3% on placebo). EASL-EASD-EASO 2026 says to choose between them by patient preference, risks and cardio-renal-metabolic profile. Semaglutide may be preferred with obesity, type 2 diabetes, established cardiovascular disease or high cardiovascular risk. Resmetirom may be prioritised without obesity, or when the patient is already on or cannot tolerate a GLP-1 receptor agonist. On semaglutide, monitoring includes nutrition and sarcopenia assessment, and fibrosis NITs are used over time to judge response. In MASH cirrhosis, resmetirom and semaglutide appear safe but should not be used as MASH-targeted treatment until liver-related benefit is shown. Pioglitazone or vitamin E remain options under the AASLD 2023 guidance. Neither resmetirom nor semaglutide has been formally studied in MetALD. Manage cardiometabolic risk in every patient whatever the fibrosis stage, including statins for ASCVD and control of glucose and blood pressure. On semaglutide, watch for GI side effects and rare risks (AKI, gallbladder disease, pancreatitis, retinopathy, loss of lean mass). For MetALD, treat moderate or severe alcohol use disorder with medication plus behavioural therapy, correct micronutrient deficiencies (folate, thiamine, vitamin D), and do not offer bariatric or endobariatric procedures. HCC surveillance with ultrasound, with or without AFP, every 6 months is indicated only when cirrhosis is present.
Clinical takeawayNo change to portal pressure assessment yet: a preliminary exploratory analysis of an ongoing study, with poor agreement against HVPG in portosinusoidal vascular disorder and MASLD.
What it foundIn 90 patients, EUS-PPG predicted decompensation better than HVPG (C-index 0.78 vs 0.56); no patient who decompensated had EUS-PPG below 10 mmHg, while 60.7% had HVPG below 10; the optimal threshold was 12 mmHg. Agreement with HVPG was poor overall (ICC 0.08).
ContextChallenges HVPG as the gold standard, especially in conditions with presinusoidal components, and suggests EUS-PPG may offer better prognostic discrimination in alcohol- or viral-related liver disease.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases (AASLD), Kaplan DE, Ripoll C, Thiele M, et al. "AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis." Hepatology. 2024;79(5):1180-1211.ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Scope: this primary document covers portal hypertension and varices in cirrhosis ONLY. Everything else in the current entry (HCC surveillance, transplant referral, nutrition, vaccination, ascites/SBP/HE/HRS/ACLF management) belongs to the separate documents listed as supporting sources and must not be attributed to this guidance. Risk-stratify compensated advanced chronic liver disease (cACLD) with non-invasive tests before defaulting to endoscopy. By vibration-controlled transient elastography, liver stiffness (LSM) under 10 kPa excludes cACLD, 10 to 14.9 kPa is suggestive and warrants further testing, and 15 kPa or above rules cACLD in. Clinically significant portal hypertension (CSPH, i.e. HVPG above 10 mm Hg) is ruled in non-invasively by LSM at or above 25 kPa alone, or LSM 20 to 24.9 kPa with platelets below 150 x 10^9/L, or LSM 15 to 19.9 kPa with platelets below 110 x 10^9/L. Where spleen stiffness measurement is available, values below 21 kPa argue against CSPH and above 50 kPa argue for it. These non-invasive cutoffs are conditional probability thresholds, not universal diagnostic rules, and hold only when their derivation conditions are met. They were established in compensated advanced chronic liver disease of viral (treated or untreated HBV/HCV), alcohol-related, or non-obese (BMI under 30) MASLD etiology, and are not validated for and should not be applied to cholestatic (e.g. PBC, PSC), vascular, or other etiologies, in which different cutoffs apply. They also require a technically reliable liver stiffness measurement by vibration-controlled transient elastography, fasting, at least 10 valid acquisitions, and an IQR/median ratio below 30 percent, and are confounded by factors that raise liver stiffness independently of fibrosis, including ALT flares or acute hepatitis, extrahepatic cholestasis, hepatic congestion (right heart failure), and recent food intake; Baveno VII recommends confirming an LSM-based rule-in on a repeat measurement obtained on a separate day. The spleen stiffness cutoffs apply only to a dedicated 100 Hz spleen module, carry a higher technical failure rate, are machine-dependent, and are not interchangeable with values obtained using the standard 50 Hz liver probe. Where these population or acquisition conditions are not met, the numeric thresholds do not reliably classify CSPH, and HVPG measurement or endoscopy is required rather than a non-invasive determination. Preserve the gray zone: LSM 15 to 25 kPa without a qualifying platelet count is explicitly indeterminate (roughly 40 to 60 percent of cACLD patients) and calls for HVPG and/or endoscopy rather than assumption in either direction. Once CSPH is established, offer a non-selective beta-blocker, carvedilol preferred at 12.5 mg/day, to lower portal pressure and prevent FIRST decompensation, on the strength of PREDESCI. This is a treat-the-pressure strategy rather than a treat-the-varices one: because a patient already on NSBB for CSPH would not have management changed by the finding, screening endoscopy becomes unnecessary for most such patients. Screening EGD is still indicated where elastography is unavailable, technically difficult, or gives discordant results, and for patients who do not meet non-invasive criteria. Standard beta-blocker contraindications (severe asthma, advanced heart block, bradyarrhythmias) continue to apply. For varices needing treatment managed endoscopically, band ligation is repeated every 2 to 4 weeks until obliteration, with surveillance endoscopy at 6 months and annually thereafter. Gastric/cardiofundal varices are treated with cyanoacrylate injection or EUS-guided coil embolization rather than banding, with hepatology involvement. In acute variceal hemorrhage, consider preemptive (early) TIPS within 24 to 72 hours in high-risk patients: Child-Turcotte-Pugh class B with score above 7 and active bleeding at endoscopy despite vasoactive therapy, or CTP class C with score 10 to 13. Keep the document's own qualifier: there is no established universal MELD or CTP cutoff at which TIPS is mandatory, and the decision is case-by-case with hepatology consultation. Statin use in compensated cirrhosis is NOT a recommendation traceable to this document; the current entry's statin sentence needs its own source or removal. Verification note: the Hepatology full text is paywalled (402/403 on direct fetch). Document identity, title, year, volume, pages and authorship were confirmed via Crossref and PubMed metadata; the numeric thresholds above were corroborated from two independent peer-reviewed commentaries on this specific guidance and match the Baveno VII rule-of-five, but were not read verbatim from the primary PDF. A human should confirm the exact guidance-statement wording against the full text before this entry is treated as quotation-grade.
Clinical takeawayTransient elastography is the most accurate non-invasive test here for advanced fibrosis in Wilson disease; the 8.35 kPa cut-off was optimized in 64 patients and needs validation.
What it foundTransient elastography (TE) had the best accuracy for detecting advanced fibrosis (≥F3) in Wilson Disease (AUC=0.79), with sensitivity 0.88 and specificity 0.85 at a cut-off of ≥8.35 kPa, compared to liver biopsy.
ContextThis study provides new evidence supporting the use of TE in Wilson Disease, a condition where non-invasive fibrosis assessment has been understudied. It confirms TE's utility in this specific population, which included both adult and pediatric patients.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases (AASLD), "A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases," 2023 (Hepatology 77(4):1428-1455)ShowHide
…Fulminant Wilson (acute liver failure with Coombs-negative hemolysis, AST/ALT >2, low ALP, low uric acid) or decompensated cirrhosis warrants emergency transfer for liver transplant evaluation.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Confirm the diagnosis with the Leipzig score integrating Kayser-Fleischer rings, ceruloplasmin, 24-hour urinary copper, hepatic copper, and ATP7B testing, then treat with lifelong therapy: symptomatic patients begin decoppering with a chelator, either D-penicillamine or trientine, and transition to maintenance once decoppering is achieved, while asymptomatic or presymptomatic patients may begin with a lower-dose chelator or zinc; maintenance may be a lower-dose chelator (D-penicillamine or trientine) or full-dose zinc. Fulminant Wilson (acute liver failure with Coombs-negative hemolysis, AST/ALT >2, low ALP, low uric acid) or decompensated cirrhosis warrants emergency transfer for liver transplant evaluation. Screen all first-degree relatives.
Clinical takeawayRisk-stratify GI bleeding on severity and patient factors (age, shock, renal failure) rather than anticoagulant status; the anticoagulant estimates were imprecise (30-day OR 1.61, 95% CI 0.81-3.21 for DOAC), so a modest effect is not excluded.
What it foundNeither DOAC nor warfarin was significantly associated with 30-day or 1-year mortality after GIB (30-day OR 1.61, 95% CI 0.81-3.21 for DOAC; 1.30, 95% CI 0.56-3.02 for warfarin).
ContextChallenges the assumption that anticoagulation status drives mortality in GIB, refining risk stratification to include clinical presentation and comorbidities.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Forkosh E … Talmon A · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗Permalink
Hepatologyretrospective · n=223 · Oct 20, 2026 · J Gastro Hep · IF 3.5
Clinical takeawayOlder age, alcohol, T2DM, chronic HBV and obesity flag SLD patients at higher fibrosis risk in an HBV-endemic population; score performance varied by age (NFS best overall, AUROC 0.724; FIB-4 best under 50) in this single-centre biopsy cohort.
What it foundOlder age (OR: 1.04), alcohol consumption (OR: 5.77), T2DM (OR: 2.13), chronic HBV infection (OR: 2.52), and obesity (OR: 2.64) were independent risk factors for advanced fibrosis in SLD patients. In nonelder patients, older age (OR: 1.10) and obesity (OR: 3.75) were significant. In the MASLD subgroup, older age (OR: 1.04), hypertension (OR: 2.31), T2DM (OR: 3.07), and chronic HBV infection (OR: 3.59) remained significant.
ContextThis study confirms known risk factors for advanced fibrosis in SLD and highlights their relevance in nonelder and MASLD patients, refining risk stratification in HBV-endemic populations.
Reinforcessuggested applicable standard· American Diabetes Association Professional Practice Committee, "6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026," Diabetes Care 2026;49(Supplement_1):S132-S149ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Manage diabetes in GI/hepatology patients by individualizing the A1c target to the population, in cirrhosis, A1c is unreliable because altered red blood cell turnover typically underestimates glycemia, so set glycemic goals using blood glucose monitoring and/or CGM rather than a fixed A1c cutoff, and in diabetic gastroparesis individualize the target rather than applying a universal cutoff; ≤7% pre-bariatric, <6.5% pre-conception, while screening all T2DM for MASLD with FIB-4, screening T1DM for concurrent celiac disease, and screening for diabetic gastroparesis when chronic nausea, early satiety, or postprandial fullness are present. Evaluate new-onset DM after age 50 without obesity for a pancreatic cancer differential, and coordinate peri-procedural medication holds and multidisciplinary endocrinology involvement.
Clinical takeawayNo clinical action yet: this is a discussion article raising awareness of steatotic liver disease prevalence.
What it foundSteatotic liver disease affects an estimated 1.7 billion people worldwide, including most individuals with obesity or type 2 diabetes.
ContextConfirms the global burden of steatotic liver disease, aligning with prior evidence on its association with obesity and type 2 diabetes.
Emergingsuggested applicable standard· American Gastroenterological Association, 'AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity' (Grunvald E et al., Gastroenterology 2022;163(5):1198-1225). DOI 10.1053/j.gastro.2022.08.045, PMID 36273831.ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
PRIMARY, AGA 2022 (pharmacotherapy, the GI-society spine): Manage obesity as a chronic disease with lifestyle intervention as the foundation. In adults with BMI ≥30 kg/m², OR BMI ≥27 kg/m² with a weight-related complication, who have an inadequate response to lifestyle intervention alone, the AGA STRONGLY recommends ADDING long-term pharmacotherapy to (not replacing) continued lifestyle intervention. Among agents the AGA suggests semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER (all moderate-certainty evidence), and, as lower-certainty options, e.g., where cost is a barrier, phentermine and diethylpropion (low-certainty evidence); when prioritizing for greatest weight loss the panel favored semaglutide 2.4 mg. The AGA suggests AGAINST orlistat and made no recommendation on Gelesis100 (identified as a knowledge gap). Agent choice should be individualized to comorbidities, contraindications, patient preference, and cost/access. COMORBIDITY BRANCHES (attributed separately, NOT part of the AGA document): For obesity-associated MASH, AASLD Practice Guidance supports selecting patients with stage F2-F3 fibrosis by non-invasive tests (VCTE ~8-15 kPa, MRE 3.1-4.4 kPa, or ELF 9.2-10.5) rather than mandatory biopsy, and endorses resmetirom (thyroid hormone receptor-β agonist; FDA-approved March 2024) as the only currently approved pharmacotherapy for MASH (not indicated for MASH cirrhosis). For metabolic/bariatric surgery, the 2022 ASMBS/IFSO indications recommend surgery at BMI ≥35 kg/m² regardless of comorbidity and consideration at BMI 30-34.9 kg/m² with metabolic disease (lower Asian-population thresholds: offer surgery at BMI >27.5, clinical obesity from >25), with multidisciplinary pre-operative evaluation. Concurrently screen for and manage the GI/hepatology comorbidities of obesity (MASLD/MASH, GERD, cholelithiasis).
Clinical takeawayFollow existing guidelines for incidentaloma management, prioritizing least invasive tests, size-based triage, and multidisciplinary review when needed.
What it foundIncidentaloma management guidelines emphasize least invasive tests, size-based triage, growth and morphology assessment, reserve tissue sampling, and referral of indeterminate lesions.
ContextConfirms and synthesizes current guidelines for incidentaloma management, highlighting commonalities and differences in intervention thresholds, second-line tests, and surveillance duration, and reviews ethical dilemmas such as disclosure conflicts and care cascades.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Raghavendra SR … Dahiya DS · Journal of Gastroenterology and Hepatology · IF 3.5 · PubMed ↗Permalink
Hepatologyprospective cohort · n=30 · Oct 23, 2026 · Hepatology · IF 18.0
Clinical takeawayNo clinical action yet: a mechanistic finding in human liver biopsies and organoid cultures, identifying SAA-FPR2 pathway as a potential therapeutic target.
What it foundCirculating serum amyloid A (SAA) levels were elevated in alcohol-related hepatitis (AH) and associated with reduced survival.
ContextThis study provides new insights into the cellular heterogeneity and dynamics in ALD progression, dissecting AH at a single-cell level.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Martínez-Álvarez A … Pose E · Hepatology · IF 18.0 · PubMed ↗Permalink